Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic reserve changes with TACE versus TACE plus sorafenib in hepatocellular carcinoma
ChiCTR-ONRC-12002277Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Indocyanine green retention at 15 minutes. Started Sep 2012; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002277.